All Stories

  1. CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo

    Article • PLoS Pathogens, December 2023, PLOS

    Matthew Frieman

  2. Diet-induced obesity and diabetes enhance mortality and reduce vaccine efficacy for SARS-CoV-2

    Article • Journal of Virology, November 2023, ASM Journals

    Matthew Frieman

  3. Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance

    Article • Journal of Allergy and Clinical Immunology, November 2023, Elsevier

    Matthew Frieman

  4. Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses

    Article • mBio, October 2023, ASM Journals

    Matthew Frieman

  5. SIRT-1 is required for release of enveloped enteroviruses

    Article • eLife, October 2023, eLife

    Matthew Frieman

  6. Systematic functional interrogation of SARS-CoV-2 host factors using Perturb-seq

    Article • Nature Communications, October 2023, Springer Science + Business Media

    Matthew Frieman

  7. SIRT-1 is required for release of enveloped enteroviruses

    Article • October 2023, eLife

    Matthew Frieman

  8. Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera

    Article • September 2023, Cold Spring Harbor Laboratory Press

    Professor (Associate) Bart L. Haagmans, Matthew Frieman

  9. SARS-CoV-2 ORF8 modulates lung inflammation and clinical disease progression

    Article • September 2023, openRxiv

    Matthew Frieman

  10. SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection

    Article • mBio, June 2023, ASM Journals

    Matthew Frieman

  11. SIRT-1 is required for release of enveloped picornaviruses

    Article • June 2023, eLife

    Matthew Frieman

  12. Association of Nirmatrelvir/Ritonavir treatment and COVID-19 neutralizing antibody titers in a longitudinal healthcare worker cohort

    Article • June 2023, openRxiv

    Matthew Frieman

  13. CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo

    Article • June 2023, openRxiv

    Matthew Frieman

  14. A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8

    Article • Nature Communications, May 2023, Springer Science + Business Media

    Matthew Frieman

  15. Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients

    Article • PLoS Computational Biology, May 2023, PLOS

    Matthew Frieman

  16. Virology under the Microscope—a Call for Rational Discourse

    Article • mSphere, April 2023, ASM Journals

    Matthew Frieman

  17. Publisher Correction: Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice

    Article • npj Vaccines, March 2023, Springer Science + Business Media

    Matthew Frieman

  18. Virology under the Microscope—a Call for Rational Discourse

    Article • Journal of Virology, February 2023, ASM Journals

    Western Research Chair in Viral Pathogenesis Miguel Quinones-Mateu, Matthew Frieman

  19. Virology under the Microscope—a Call for Rational Discourse

    Article • mBio, February 2023, ASM Journals

    Western Research Chair in Viral Pathogenesis Miguel Quinones-Mateu, Matthew Frieman

  20. Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants

    Article • Nature Communications, February 2023, Springer Science + Business Media

    Matthew Frieman

  21. Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice

    Article • npj Vaccines, February 2023, Springer Science + Business Media

    Matthew Frieman

  22. Dipeptidyl Peptidase 4/Midline‐1 Axis Promotes T Lymphocyte Motility in Atherosclerosis

    Article • Advanced Science, January 2023, Wiley

    Matthew Frieman

  23. Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice

    Article • Scientific Reports, January 2023, Springer Science + Business Media

    Matthew Frieman

  24. The mRNA vaccine BNT162b2 demonstrates impaired TH1 immunogenicity in human elders in vitro and aged mice in vivo

    Article • December 2022, Springer Science + Business Media

    Matthew Frieman

  25. Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection

    Article • mSphere, December 2022, ASM Journals

    Matthew Frieman

  26. Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance

    Article • December 2022, openRxiv

    Matthew Frieman

  27. Enhancing the Protection of Influenza Virus Vaccines with BECC TLR4 Adjuvant in Aged Mice

    Article • November 2022, Springer Science + Business Media

    Matthew Frieman

  28. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

    Article • The Lancet Infectious Diseases, November 2022, Elsevier

    Matthew Frieman

  29. Exhaled Breath Aerosol Shedding of Highly Transmissible Versus Prior Severe Acute Respiratory Syndrome Coronavirus 2 Variants

    Article • Clinical Infectious Diseases, October 2022, Oxford University Press (OUP)

    Matthew Frieman

  30. Diet Induced Obesity and Diabetes Enhance Mortality and Reduces Vaccine Efficacy for SARS-CoV-2

    Article • October 2022, openRxiv

    Matthew Frieman

  31. Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection

    Article • Scientific Reports, October 2022, Springer Science + Business Media

    Matthew Frieman

  32. A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8

    Article • October 2022, openRxiv

    Matthew Frieman

  33. Enhancing the Protection of Influenza Virus Vaccines with BECC TLR4 Adjuvant in Aged Mice

    Article • September 2022, Research Square

    Dr Robert Ernst, Matthew Frieman

  34. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2

    Article • Frontiers in Immunology, September 2022, Frontiers

    Matthew Frieman

  35. Self-assembling short immunostimulatory duplex RNAs with broad-spectrum antiviral activity

    Article • Molecular Therapy — Nucleic Acids, September 2022, Elsevier

    Matthew Frieman

  36. SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis

    Article • Proceedings of the National Academy of Sciences, August 2022, Proceedings of the National Academy of Sciences

    Matthew Frieman

  37. Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine

    Article • Science Translational Medicine, August 2022, American Association for the Advancement of Science

    Matthew Frieman

  38. SIRT-1 is required for release of enveloped enteroviruses

    Article • August 2022, openRxiv

    Matthew Frieman

  39. PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19

    Article • Communications Biology, August 2022, Springer Science + Business Media

    Matthew Frieman

  40. mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant

    Article • Communications Biology, August 2022, Springer Science + Business Media

    Matthew Frieman

  41. Evolution of SARS-CoV-2 Shedding in Exhaled Breath Aerosols

    Article • July 2022, openRxiv

    Matthew Frieman

  42. Systematic functional interrogation of SARS-CoV-2 host factors using Perturb-seq

    Article • July 2022, openRxiv

    Matthew Frieman

  43. SARS-CoV-2 Variant Spike and accessory gene mutations alter pathogenesis

    Article • June 2022, openRxiv

    Matthew Frieman

  44. Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease

    Article • npj Vaccines, May 2022, Springer Science + Business Media

    Matthew Frieman

  45. PIKfyve-specific inhibitors restrict replication of multiple human coronaviruses in vitro but not in a murine model of COVID-19

    Article • April 2022, Springer Science + Business Media

    Matthew Frieman

  46. mRNA booster vaccination protects extremely aged mice against the SARS-CoV-2 Omicron variant

    Article • April 2022, Springer Science + Business Media

    Matthew Frieman

  47. Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients

    Article • April 2022, openRxiv

    Matthew Frieman

  48. Defining the risk of SARS-CoV-2 variants on immune protection

    Article • Nature, March 2022, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Dr. Louis-Marie Bloyet, Matthew Frieman

  49. Inhibition of the IFN-α JAK/STAT Pathway by MERS-CoV and SARS-CoV-1 Proteins in Human Epithelial Cells

    Article • Viruses, March 2022, MDPI AG

    Matthew Frieman

  50. Host Cell Glycocalyx Remodeling Reveals SARS-CoV-2 Spike Protein Glycomic Binding Sites

    Article • Frontiers in Molecular Biosciences, March 2022, Frontiers

    Matthew Frieman

  51. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19

    Article • March 2022, openRxiv

    Matthew Frieman

  52. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

    Article • Science Translational Medicine, March 2022, American Association for the Advancement of Science

    Matthew Frieman

  53. Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2

    Article • Nature, February 2022, Springer Science + Business Media

    Matthew Frieman

  54. An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity

    Article • Cell, February 2022, Elsevier

    Matthew Frieman

  55. WITHDRAWN: SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer’s-like neuropathology

    Article • February 2022, openRxiv

    Matthew Frieman

  56. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice

    Article • Science Translational Medicine, January 2022, American Association for the Advancement of Science

    Matthew Frieman

  57. A SARS-CoV-2 Delta Variant Case Manifesting as Extensive Placental Infection and Fetal Transmission

    Article • Gynecologic and Obstetric Investigation, January 2022, Karger Publishers

    Matthew Frieman

  58. Magnitude and breadth of neutralizing antibody responses elicited by SARS-CoV-2 infection or vaccination

    Article • January 2022, openRxiv

    Matthew Frieman

  59. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses

    Article • mBio, December 2021, ASM Journals

    Matthew Frieman

  60. Mucosal and systemic responses to SARS-CoV-2 vaccination in infection naïve and experienced individuals

    Article • December 2021, openRxiv

    Matthew Frieman

  61. Self-assembling short immunostimulatory duplex RNAs with broad spectrum antiviral activity

    Article • November 2021, openRxiv

    Matthew Frieman

  62. Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease

    Article • November 2021, openRxiv

    Matthew Frieman

  63. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

    Article • Nature Communications, October 2021, Springer Science + Business Media

    Matthew Frieman

  64. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

    Article • Nature Microbiology, September 2021, Springer Science + Business Media

    Matthew Frieman

  65. Viral RNA and Infectious Influenza Virus on Mobile Phones of Patients With Influenza in Hong Kong and the United States

    Article • The Journal of Infectious Diseases, September 2021, Oxford University Press (OUP)

    Matthew Frieman

  66. Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection

    Article • Clinical Infectious Diseases, September 2021, Oxford University Press (OUP)

    Matthew Frieman

  67. An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice

    Article • September 2021, openRxiv

    Matthew Frieman

  68. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

    Article • Cell Reports Medicine, September 2021, Elsevier

    Matthew Frieman

  69. Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection

    Article • August 2021, openRxiv

    Matthew Frieman

  70. Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection

    Article • Vaccine, August 2021, Elsevier

    Matthew Frieman

  71. High confidence identification of intra-host single nucleotide variants for person-to-person influenza transmission tracking in congregate settings

    Article • July 2021, openRxiv

    Matthew Frieman

  72. Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection

    Article • June 2021, openRxiv

    Matthew Frieman

  73. Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants

    Article • June 2021, openRxiv

    Matthew Frieman

  74. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors

    Article • EBioMedicine, June 2021, Elsevier

    Matthew Frieman

  75. Functional landscape of SARS-CoV-2 cellular restriction

    Article • Molecular Cell, June 2021, Elsevier

    Matthew Frieman

  76. Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity

    Article • May 2021, openRxiv

    Matthew Frieman

  77. A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics

    Article • Nature Biomedical Engineering, May 2021, Springer Science + Business Media

    Dr Randy A Albrecht, Matthew Frieman

  78. The Great Deceiver: miR-2392’s Hidden Role in Driving SARS-CoV-2 Infection

    Article • April 2021, openRxiv

    Matthew Frieman

  79. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

    Article • JAMA, April 2021, American Medical Association (AMA)

    Matthew Frieman

  80. Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV‑2 and Potential Mechanisms

    Article • ACS Omega, March 2021, American Chemical Society (ACS)

    Matthew Frieman

  81. Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

    Article • February 2021, Springer Science + Business Media

    Matthew Frieman

  82. Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

    Article • February 2021, openRxiv

    Matthew Frieman

  83. Development and deployment of COVID-19 vaccines for those most vulnerable

    Article • Science Translational Medicine, February 2021, American Association for the Advancement of Science

    Matthew Frieman

  84. Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2

    Article • February 2021, openRxiv

    Matthew Frieman

  85. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

    Article • January 2021, Cold Spring Harbor Laboratory Press

    Dr James E Crowe, Matthew Frieman

  86. Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus

    Article • The Journal of Infectious Diseases, January 2021, Oxford University Press (OUP)

    Matthew Frieman

  87. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

    Article • Nature Communications, January 2021, Springer Science + Business Media

    Matthew Frieman

  88. Collaboration between the Fab and Fc Contribute to Maximal Protection Against SARS-CoV-2 Following NVX-CoV2373 Subunit Vaccine with Matrix-M™ Vaccination

    Article • January 2021, Elsevier

    Matthew Frieman

  89. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2020, New England Journal of Medicine (NEJM/MMS)

    Matthew Frieman

  90. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms

    Article • Science, December 2020, American Association for the Advancement of Science

    Matthew Frieman

  91. Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms

    Article • December 2020, openRxiv

    Matthew Frieman

  92. The SKI complex is a broad-spectrum, host-directed antiviral drug target for coronaviruses, influenza, and filoviruses

    Article • Proceedings of the National Academy of Sciences, November 2020, Proceedings of the National Academy of Sciences

    Matthew Frieman

  93. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

    Article • Vaccine, November 2020, Elsevier

    Matthew Frieman

  94. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo

    Article • Journal of Virology, October 2020, ASM Journals

    Matthew Frieman

  95. Functional Landscape of SARS-CoV-2 Cellular Restriction

    Article • September 2020, openRxiv

    Matthew Frieman

  96. Animal models for COVID-19

    Article • Nature, September 2020, Springer Science + Business Media

    Professor (Associate) Bart L. Haagmans, Dr Randy A Albrecht, Dr Jens H. Kuhn, Matthew Frieman

  97. Coronavirus interactions with the cellular autophagy machinery

    Article • Autophagy, September 2020, Taylor & Francis

    Matthew Frieman

  98. Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

    Article • September 2020, openRxiv

    Matthew Frieman

  99. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

    Article • Nature Communications, August 2020, Springer Science + Business Media

    Johan Neyts, Matthew Frieman

  100. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

    Article • Science, August 2020, American Association for the Advancement of Science

    Matthew Frieman

  101. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

    Article • August 2020, openRxiv

    Matthew Frieman

  102. First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

    Article • August 2020, openRxiv

    Matthew Frieman

  103. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

    Article • July 2020, Springer Science + Business Media

    Matthew Frieman

  104. The SKI complex is a broad-spectrum antiviral drug target

    Article • Access Microbiology, July 2020, Society for General Microbiology

    Matthew Frieman

  105. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

    Article • June 2020, openRxiv

    Matthew Frieman

  106. Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles

    Article • ACS Nano, May 2020, American Chemical Society (ACS)

    Matthew Frieman

  107. COVID-19: Knowns, Unknowns, and Questions

    Article • mSphere, April 2020, ASM Journals

    Matthew Frieman

  108. Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics

    Article • April 2020, openRxiv

    Matthew Frieman

  109. Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo

    Article • March 2020, openRxiv

    Matthew Frieman

  110. Using Yeast to Identify Coronavirus–Host Protein Interactions

    Article • January 2020, Springer Science + Business Media

    Matthew Frieman

  111. Functional Landscape of SARS-CoV-2 Cellular Restriction

    Article • January 2020, Elsevier

    Matthew Frieman

  112. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection

    Article • JCI Insight, October 2019, American Society for Clinical Investigation

    Matthew Frieman

  113. A Yeast Suppressor Screen Used To Identify Mammalian SIRT1 as a Proviral Factor for Middle East Respiratory Syndrome Coronavirus Replication

    Article • Journal of Virology, August 2019, ASM Journals

    Matthew Frieman

  114. Bats and Coronaviruses

    Article • Viruses, January 2019, MDPI AG

    Matthew Frieman

  115. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors

    Article • Journal of General Virology, May 2018, Society for General Microbiology

    Matthew Frieman

  116. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells

    Article • PLOS One, March 2018, PLOS

    Matthew Frieman

  117. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors

    Article • January 2018, openRxiv

    Matthew Frieman

  118. Respiratory Viruses

    Article • January 2018, Elsevier

    Matthew Frieman

  119. Monocyte DPP4 Expression in Human Atherosclerosis Is Associated With Obesity and Dyslipidemia

    Article • Diabetes Care, November 2017, American Diabetes Association

    Matthew Frieman

  120. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis

    Article • Antiviral Research, July 2017, Elsevier

    Matthew Frieman

  121. Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection

    Article • Journal of Virology, April 2017, ASM Journals

    Matthew Frieman

  122. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

    Article • Vaccine, March 2017, Elsevier

    Matthew Frieman

  123. One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus

    Article • Journal of Virology, November 2016, ASM Journals

    Dr Matthias Johannes Schnell, Matthew Frieman

  124. CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome

    Article • Journal of Virology, October 2016, ASM Journals

    Matthew Frieman

  125. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion

    Article • Journal of Virology, July 2016, ASM Journals

    Matthew Frieman

  126. A Universal Next-Generation Sequencing Protocol To Generate Noninfectious Barcoded cDNA Libraries from High-Containment RNA Viruses

    Article • mSystems, June 2016, ASM Journals

    Dr Reed S Shabman, Matthew Frieman

  127. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo

    Article • Science Translational Medicine, February 2016, American Association for the Advancement of Science

    Dr Jens H. Kuhn, Matthew Frieman

  128. Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross

    Article • PLoS Genetics, October 2015, PLOS

    Vineet Menachery, Matthew Frieman

  129. Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of Glycosylation Interference

    Article • Journal of Virology, September 2015, ASM Journals

    Matthew Frieman

  130. Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens

    Article • ACS Infectious Diseases, August 2015, American Chemical Society (ACS)

    Matthew Frieman

  131. The Global Virus Network: Challenging chikungunya

    Article • Antiviral Research, August 2015, Elsevier

    Professor Marc Lecuit, Matthew Frieman

  132. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

    Article • Proceedings of the National Academy of Sciences, June 2015, Proceedings of the National Academy of Sciences

    Matthew Frieman

  133. SINC, a type III secreted protein of Chlamydia psittaci, targets the inner nuclear membrane of infected cells and uninfected neighbors

    Article • Molecular Biology of the Cell, May 2015, American Society for Cell Biology (ASCB)

    Matthew Frieman

  134. Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding

    Article • Molecular Immunology, May 2015, Elsevier

    Matthew Frieman

  135. Growth and Quantification of MERS‐CoV Infection

    Article • Current Protocols in Microbiology, May 2015, Wiley

    Matthew Frieman

  136. Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ

    Article • Clinical Immunology, April 2015, Elsevier

    Matthew Frieman

  137. Foreword

    Article • Virus Research, April 2015, Elsevier

    Matthew Frieman

  138. Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis

    Article • Antimicrobial Agents and Chemotherapy, December 2014, ASM Journals

    Dr Jens H. Kuhn, Matthew Frieman

  139. Foreword

    Article • Virus Research, December 2014, Elsevier

    Matthew Frieman

  140. The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity

    Article • Virology Journal, December 2014, Springer Science + Business Media

    Matthew Frieman

  141. Treating MERS-CoV during an outbreak

    Article • The Lancet Infectious Diseases, November 2014, Elsevier

    Matthew Frieman

  142. Standards for Sequencing Viral Genomes in the Era of High-Throughput Sequencing

    Article • mBio, June 2014, ASM Journals

    Dr Jens H. Kuhn, Matthew Frieman

  143. The art of war: battles between virus and host

    Article • Current Opinion in Virology, June 2014, Elsevier

    Matthew Frieman

  144. Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection

    Article • Antimicrobial Agents and Chemotherapy, May 2014, ASM Journals

    Matthew Frieman

  145. Evaluation of SSYA10-001 as a Replication Inhibitor of Severe Acute Respiratory Syndrome, Mouse Hepatitis, and Middle East Respiratory Syndrome Coronaviruses

    Article • Antimicrobial Agents and Chemotherapy, May 2014, ASM Journals

    Matthew Frieman

  146. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

    Article • Vaccine, May 2014, Elsevier

    Matthew Frieman

  147. NKT Cell Responses to B Cell Lymphoma

    Article • Medical Sciences, April 2014, MDPI AG

    Matthew Frieman

  148. The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling

    Article • Journal of General Virology, April 2014, Society for General Microbiology

    Matthew Frieman

  149. Coronaviruses: Important Emerging Human Pathogens

    Article • Journal of Virology, March 2014, ASM Journals

    Matthew Frieman

  150. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays

    Article • Journal of General Virology, March 2014, Society for General Microbiology

    Matthew Frieman

  151. Deficiency of Melanoma Differentiation–associated Protein 5 Results in Exacerbated Chronic Postviral Lung Inflammation

    Article • American Review of Respiratory Disease, February 2014, Oxford University Press (OUP)

    Matthew Frieman

  152. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus

    Article • Journal of General Virology, February 2014, Society for General Microbiology

    Matthew Frieman

  153. The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity

    Article • Virology Journal, January 2014, Springer Science + Business Media

    Matthew Frieman

  154. Emergence of the Middle East Respiratory Syndrome Coronavirus

    Article • PLoS Pathogens, September 2013, PLOS

    Matthew Frieman

  155. Induction of Alternatively Activated Macrophages Enhances Pathogenesis during Severe Acute Respiratory Syndrome Coronavirus Infection

    Article • Journal of Virology, September 2012, ASM Journals

    Matthew Frieman

  156. Evidence Supporting a Zoonotic Origin of Human Coronavirus Strain NL63

    Article • Journal of Virology, September 2012, ASM Journals

    Matthew Frieman

  157. Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from influenza

    Article • Immunology Letters, January 2012, Elsevier

    Matthew Frieman

  158. Yeast Based Small Molecule Screen for Inhibitors of SARS-CoV

    Article • PLOS One, December 2011, PLOS

    Matthew Frieman

  159. Integrative Deep Sequencing of the Mouse Lung Transcriptome Reveals Differential Expression of Diverse Classes of Small RNAs in Response to Respiratory Virus Infection

    Article • mBio, November 2011, ASM Journals

    Matthew Frieman

  160. Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease

    Article • Journal of Virology, November 2011, ASM Journals

    Matthew Frieman

  161. Severe Acute Respiratory Syndrome ( SARS )

    Article • June 2011, Wiley

    Matthew Frieman

  162. Genetic analysis of complex traits in the emerging Collaborative Cross

    Article • Genome Research, March 2011, Cold Spring Harbor Laboratory Press

    Matthew Frieman

  163. Unique Signatures of Long Noncoding RNA Expression in Response to Virus Infection and Altered Innate Immune Signaling

    Article • mBio, October 2010, ASM Journals

    Matthew Frieman

  164. Metagenomic Analysis of the Viromes of Three North American Bat Species: Viral Diversity among Different Bat Species That Share a Common Habitat

    Article • Journal of Virology, October 2010, ASM Journals

    Matthew Frieman

  165. Transcriptomic Analysis Reveals a Mechanism for a Prefibrotic Phenotype in STAT1 Knockout Mice during Severe Acute Respiratory Syndrome Coronavirus Infection

    Article • Journal of Virology, August 2010, ASM Journals

    Matthew Frieman

  166. SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a Type I, II and III Interferon Receptor Independent Mechanism

    Article • PLoS Pathogens, April 2010, PLOS

    Matthew Frieman

  167. Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus

    Article • The Journal of Infectious Diseases, March 2010, Oxford University Press (OUP)

    Matthew Frieman

  168. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo

    Article • Virology, December 2009, Elsevier

    Matthew Frieman

  169. The Open Reading Frame 3a Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Promotes Membrane Rearrangement and Cell Death

    Article • Journal of Virology, November 2009, ASM Journals

    Matthew Frieman

  170. Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection

    Article • Journal of Virology, May 2009, ASM Journals

    Professor (Associate) Bart L. Haagmans, Matthew Frieman

  171. Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease Ubiquitin-Like Domain and Catalytic Domain Regulate Antagonism of IRF3 and NF-κB Signaling

    Article • Journal of Virology, April 2009, ASM Journals

    Matthew Frieman

  172. Novel Influenza Virus NS1 Antagonists Block Replication and Restore Innate Immune Function

    Article • Journal of Virology, December 2008, ASM Journals

    Matthew Frieman

  173. Mechanisms of Severe Acute Respiratory Syndrome Pathogenesis and Innate Immunomodulation

    Article • Microbiology and Molecular Biology Reviews, December 2008, ASM Journals

    Matthew Frieman

  174. SARS coronavirus and innate immunity

    Article • Virus Research, April 2008, Elsevier

    Matthew Frieman

  175. Glycan microarray analysis of Candida glabrata adhesin ligand specificity

    Article • Molecular Microbiology, March 2008, Wiley

    Matthew Frieman

  176. Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of nsp1 and Rational Design of an Attenuated Strain

    Article • Journal of Virology, August 2007, ASM Journals

    Matthew Frieman

  177. Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi Membrane

    Article • Journal of Virology, June 2007, ASM Journals

    Matthew Frieman

  178. Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists

    Article • Journal of Virology, November 2006, ASM Journals

    Professor Luis Martinez-Sobrido, Matthew Frieman

  179. Sars Coronavirus Accessory ORFs Encode Luxury Functions

    Article • January 2006, Springer Science + Business Media

    Matthew Frieman

  180. Sars Coronavirus Vaccine Development

    Article • January 2006, Springer Science + Business Media

    Matthew Frieman

  181. Severe Acute Respiratory Syndrome Coronavirus Group-Specific Open Reading Frames Encode Nonessential Functions for Replication in Cell Cultures and Mice

    Article • Journal of Virology, December 2005, ASM Journals

    Matthew Frieman

  182. Multiple sequence signals determine the distribution of glycosylphosphatidylinositol proteins between the plasma membrane and cell wall in Saccharomyces cerevisiae

    Article • Microbiology, October 2004, Society for General Microbiology

    Matthew Frieman

  183. The ω‐site sequence of glycosylphosphatidylinositol‐anchored proteins in Saccharomyces cerevisiae can determine distribution between the membrane and the cell wall

    Article • Molecular Microbiology, October 2003, Wiley

    Matthew Frieman

  184. Modular domain structure in the Candida glabrata adhesin Epa1p, a β1,6 glucan‐cross‐linked cell wall protein

    Article • Molecular Microbiology, October 2002, Wiley

    Matthew Frieman

  185. A Genome-Wide Screen for Normally Methylated Human CpG Islands That Can Identify Novel Imprinted Genes

    Article • Genome Research, March 2002, Cold Spring Harbor Laboratory Press

    Matthew Frieman

  186. RNA Polymerase I Transcription in a Brassica Interspecific Hybrid and Its Progenitors: Tests of Transcription Factor Involvement in Nucleolar Dominance

    Article • Genetics, May 1999, Oxford University Press (OUP)

    Matthew Frieman